This program project will discover and test novel compounds as potential therapeutic agents, as well as test and discover signaling pathways as potential modifiers, of liver disease due to ?1-antitrypsin deficiency (ATD), one of the most common genetic causes of liver disease and a frequent indication for liver transplantation. The program project grew out 4 collaborations: collaboration between Drs. Perlmutter, Michalopoulos and Stolz showed that, by enhancing autophagic degradation of mutant ATZ, carbamazepine could reduce hepatic ATZ load and fibrosis in the PiZ mouse model of ATD, and therein provided evidence that endogenous proteostasis mechanisms could be targeted for therapeutics;collaboration between Drs Silverman and Perlmutter using a newly developed C. elegans model of ATD and a high-content screening platform generated a powerful engine for discovery of additional drugs and modifiers;collaboration between Drs. Bahar, Silverman and Perlmutter has added computational pharmacological strategies to potential drug discovery for ATD;collaboration between Drs. Fox, Chowdhury and Perlmutter has shown that transplanted hepatocytes will re-populate the liver of the PiZ mouse model of ATD, providing the potential for developing 'humanized'mouse models of ATD with the ultimate goal of personalized medicine for ATD. The 4 projects include: 1) testing of novel drug and modifier candidates in mammalian cell line and mouse models of ATD (Pl-Perlmutter);2) use of the C. elegans model of ATD to discover new drugs and modifiers (Pl-Silverman);3) use of sophisticated pathologic and genomic approaches to elucidate mechanisms of hepatocyte hyperproliferation in mouse models of ATD (Pl-Michalopoulos);4) repopulation studies using a new immunedeficient PiZ mouse model and iPS cell lines to develop 'humanized'mice that model ATD together with host-specific modifiers (co-PIs: Fox;Chowdhury). The S cores include: A) Cell and Tissue Imaging (Pl- Stolz);B) Computational Pharmacology (Pl-Bahar);C) Genomics (Pi-Bell). This outstanding group of investigators will use existing and develop novel model systems which together with sophisticated drug discovery tools, pathologic and genomic techniques will lead to new drugs and druggable targets for ATD.
The studies proposed in this application will use multiple model systems and analytical techniques to test potential therapeutic agents that are currently available as well as discover new drugs and novel druggable targets for ?1 antitrypsin deficiency, one of the most common genetic causes of hepatic fibrosis, cirrhosis and carcinoma in humans.
Showing the most recent 10 out of 39 publications
